Hepatic Cirrhosis.
Conditions
Interventions
Intervention 1: Intervention group: Will take 400 mg of caffeine daily in the form of two tablets each contains 200 mg of caffeine (Product of raha Company) orally for eight weeks. Intervention 2: Con
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Having desire to participate in the study Age range of 18-75 BMI between 18.5 to 30 kg per square meter Do not develop extrahepatic organ failure Do not take caffeinated drugs for one month before the start of the study Do not consume more than 3 cups of coffee per day Not pregnant or breastfeeding
Exclusion criteria
Exclusion criteria: The patient's unwillingness to continue cooperation Patients who have consumed less than 80% of the capsules. The diagnosis of the treating physician at the end of the patient's participation in the study Pregnancy or breastfeeding Loss of more than 10% of body weight during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Model for end-stage liver cirrhosis score (MELD score). Timepoint: At the beginning and the end of the study. Method of measurement: Using the formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum total billirubin. Timepoint: At the beginning and the end of the study. Method of measurement: Enzymatic method.;Serum albumin. Timepoint: At the beginning and the end of the study. Method of measurement: Enzymatic method.;Serum Alanine transaminase (ALT). Timepoint: At the beginning and the end of the study. Method of measurement: Enzymatic method.;Serum Aspartate aminotransferase (AST). Timepoint: At the beginning and the end of the study. Method of measurement: Enzymatic method.;Serum creatinine. Timepoint: At the beginning and the end of the study. Method of measurement: Enzymatic method.;Serum Na. Timepoint: At the beginning and the end of the study. Method of measurement: Enzymatic method.;Serum Alkaline phosphate (ALP). Timepoint: At the beginning and the end of the study. Method of measurement: Enzymatic method.;International normalized ratio (INR). Timepoint: At the beginning and the end of the study. Method of measurement: Calculate the ratio.;Prothrombin time (PT). Timepoint: At the beginning and the end of the study. Method of measurement: Prothrombin time measurement.;Partial thromboplastin time (PTT). Timepoint: At the beginning and the end of the study. Method of measurement: Partial Thromboplastin Time measurement.;Serum platelets. Timepoint: At the beginning and the end of the study. Method of measurement: Automatic cell count.;Tumor necrosis factor-alpha (TNF-a). Timepoint: At the beginning and the end of the study. Method of measurement: ELISA method.;Interleukin 6 (IL-6). Timepoint: At the beginning and the end of the study. Method of measurement: ELISA method.;Serum c-reactive protein (CRP). Timepoint: At the beginning and the end of the study. Method of measurement: ELISA method.;Child pugh score. Timepoint: At the beginning and the end of the study. Method of measurement: Using the formula.;Fibrosis 4 score. Timepoint: At the beginning and the end of the study. Method of measurement: Using the formula.;AST to platelets ratio index (APRI) | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzita Hekmatdoost
Shahid Beheshti University of Medical Sciences
Outcome results
None listed